Table 1.
Characteristics of ulcerative colitis patients treated with adalimumab, infliximab, and vedolizumab.
| UC patients (n = 134) | |
|---|---|
| Demographic parameters | |
| Age at study inclusion, mean years (SD) | 50.0 (17.1) |
| Age at UC diagnosis, mean years (SD) | 38.2 (16.4) |
| Sex, n (%) | |
| Male | 79 (59.0) |
| Female | 55 (41.0) |
| Life habits | |
| Alcohol use, n (%)a | |
| Excessive | 5 (3.9) |
| Moderate | 66 (52.0) |
| Former | 19 (15.0) |
| Never | 37 (29.1) |
| Tobacco use, n (%)a | |
| Current | 14 (11.1) |
| Former | 46 (36.5) |
| Never | 66(52.4) |
| Drugs use, n (%)a | |
| Current | 4 (3.4) |
| Former | 3 (2.5) |
| Never | 114 (94.2) |
| Medical parameters | |
| Extent at diagnosis, n (%)a | |
| E1—Proctitis | 18 (15.5) |
| E2—Left-sided colitis | 45 (38.8) |
| E3—Pancolitis | 53 (45.7) |
| Comorbidities, n (%) | |
| Respiratory disease | 28 (20.9) |
| High blood pressure | 27 (20.1) |
| Diabetes | 13 (9.7) |
| Cardiovascular disease | 13 (9.7) |
| Arthritis | 12 (9.0) |
| Cancer | 7 (4.6) |
| Treatment exposure | |
| First biological used, n (%) | |
| Adalimumab | 51 (38.1) |
| Infliximab | 59 (44.0) |
| Vedolizumab | 20 (14.9) |
| Othersb | 4 (3.0) |
| Colectomy, n (%) | 10 (7.5) |
Abbreviations: SD, standard deviation; UC, ulcerative colitis.
Proportion calculated on total available data.
Includes exposure to golimumab.